benzinga.comCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communicationsabout 1 year ago
benzinga.comCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemiaabout 1 year ago
benzinga.comCellectis Announces Completion of the Additional Equity Investment by AstraZenecaabout 1 year ago
benzinga.comCellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsabout 1 year ago
benzinga.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsover 1 year ago
CashuCellectis Collaborates to Enhance Gene Editing for Next-Generation Cancer Therapiesabout 6 hours ago